Compare GSK plc (GSK) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs L3Harris Technologies Inc — how do they compare? GSK plc trades at $52.75 (market cap $101.34B), while L3Harris Technologies Inc trades at $284.46 (market cap $53.43B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | LHX | |
|---|---|---|
Market Cap | $101.34B | $53.43B |
Sector | Health | Industrials |
52-Week High | $61.18 | $378.48 |
52-Week Low | $36.20 | $263.09 |
Enterprise Value | $121.95B | $64.20B |
Dividend Yield | 3.49% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
LHX trades at $290.01, up 0.46% with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $21.87B in 2025 and strong analyst support with 75% buy ratings. Recent contract wins with the U.S. Space Force and Army highlight ongoing defense sector strength. Cash flow improved to $454M net in 2025, though debt levels remain elevated at 26.98% debt-to-asset ratio.
LHX presents a compelling value opportunity with a $367.50 consensus price target representing 27% upside. Defense spending tailwinds and record $40.7B backlog support growth, but investors face risks from execution challenges and geopolitical dependency. The stock's current valuation at 31.14 P/E appears reasonable given earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
